Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.
Atuliflapon
human mass balance
metabolism
pharmacokinetics
radiolabeled study
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
27
06
2024
received:
21
03
2024
accepted:
27
09
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
14
10
2024
Statut:
ppublish
Résumé
In this study, the mass balance, pharmacokinetics (PK) and metabolism of atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor, were investigated in healthy male subjects. A single oral dose of 200 mg [
Substances chimiques
5-Lipoxygenase-Activating Protein Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70029Subventions
Organisme : AstraZeneca
Informations de copyright
© 2024 AstraZeneca. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
Références
Peters‐Golden M, Henderson WR. Leukotrienes. N Engl J Med. 2007;357(18):1841‐1854. doi:10.1056/NEJMra071371
Hakonarson H, Thorvaldsson S, Helgadottir A, et al. Effects of a 5‐lipoxygenase‐activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA. 2005;293(18):2245‐2256. doi:10.1001/jama.293.18.2245
Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation. 1998;97(24):2406‐2413. doi:10.1161/01.cir.97.24.2406
Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5‐lipoxygenase pathway within the arterial wall during human atherogenesis. Proceedings of the National Academy of Sciences. 2003;100(3):1238‐1243. doi:10.1073/pnas.242716099
Cipollone F, Mezzetti A, Fazia ML, et al. Association between 5‐lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25(8):1665‐1670. doi:10.1161/01.ATV.0000172632.96987.2d
Sánchez‐Galán E, Gómez‐Hernández A, Vidal C, et al. Leukotriene B4 enhances the activity of nuclear factor‐kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res. 2009;81(1):216‐225. doi:10.1093/cvr/cvn277
Carry M, Korley V, Willerson JT, Weigelt L, Ford‐Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5‐lipoxygenase activation. Circulation. 1992;85(1):230‐236. doi:10.1161/01.cir.85.1.230
Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5‐lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36(3):233‐239. doi:10.1038/ng1311
Yasuda Y, Cohen CD, Henger A, Kretzler M. Gene expression profiling analysis in nephrology: towards molecular definition of renal disease. Clin Exp Nephrol. 2006;10(2):91‐98. doi:10.1007/s10157-006-0421-z
Sampson AP. FLAP Inhibitors for the Treatment of Inflammatory Diseases. Current Opinion in Investigational Drugs. Vol 10. 2000; 2009:1163‐1172.
Lemurell M, Ulander J, Emtenäs H, et al. Novel chemical series of 5‐lipoxygenase‐activating protein inhibitors for treatment of coronary artery disease. J Med Chem. 2019;62(9):4325‐4349. doi:10.1021/acs.jmedchem.8b02012
Ericsson H, Nelander K, Lagerstrom‐Fermer M, et al. Initial clinical experience with AZD5718, a novel once daily Oral 5‐lipoxygenase activating protein inhibitor. Clin Transl Sci. 2018;11(3):330‐338. doi:10.1111/cts.12546
Knöchel J, Nelander K, Heijer M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of AZD5718, an oral 5‐lipoxygenase‐activating protein (FLAP) inhibitor, in healthy japanese male subjects. Clin Drug Investig. 2021;41(10):895‐905. doi:10.1007/s40261-021-01078-7
Prescott E, Angerås O, Erlinge D, et al. Safety and efficacy of the 5‐lipoxygenase‐activating protein inhibitor AZD5718 in patients with recent myocardial infarction: the phase 2a FLAVOUR study. Int J Cardiol. 2022;365:34‐40. doi:10.1016/j.ijcard.2022.07.016
Heerspink H, Law G, Psachoulia K, et al. Design of FLAIR: a phase 2b study of the 5‐lipoxygenase activating protein inhibitor AZD5718 in patients with Proteinuric CKD. Kidney International Reports. 2021;6(11):2803‐2810. doi:10.1016/j.ekir.2021.08.018
Heerspink H, Ufnal M, Law C, et al. A phase IIb randomised, double blind, placebo controlled, multi centre, dose‐ranging study of Atuliflapon in participants with proteinuric CKD:FR‐PO979. Journal of the American Society of Nephrology. 2023;34(11S):677‐678. doi:10.1681/ASN.20233411S1677c
Bain G, King CD, Rewolinski M, et al. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5‐lipoxygenase‐activating protein (FLAP). Clin Pharmacol Ther. 2010;87(4):437‐444. doi:10.1038/clpt.2009.301
Depré M, Friedman B, Van Hecken A, et al. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK‐0591, a 5‐lipoxygenase‐activating protein inhibitor. Clin Pharmacol Ther. 1994;56(1):22‐30. doi:10.1038/clpt.1994.96
Coppola P, Andersson A, Cole S. The importance of the human mass balance study in regulatory submissions. CPT Pharmacometrics Syst Pharmacol. 2019;8(11):792‐804. doi:10.1002/psp4.12466
Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources Preface. www.gov.uk/arsac 2019.
Hamilton R, Garnett W, Kline B. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther. 1981;29(3):408‐413. doi:10.1038/clpt.1981.56
Harding SD, Sharman JL, Faccenda E, et al. NC‐IUPHAR, the IUPHAR/BPS guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to Immunopharmacology. Nucleic Acids Res. 2018;46:D1091‐D1106. doi:10.1093/nar/gkx1121
Alexander SPH, Fabbro D, Kelly E, et al. The concise guide to pharmacology 2023/24: enzymes. Br J Pharmacol. 2023;180(2):S289‐s373. doi:10.1111/bph.16181
Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 2007;39(1):17‐43. doi:10.1080/03602530600952172
Wong SG, Ma S. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites‐in‐safety testing (MIST) in drug development. In: He K, Hollenberg PF, Wienkers LC, eds. Overcoming Obstacles in Drug Discovery and Development. Academic Press; 2023:137‐174. doi:10.1016/B978-0-12-817134-9.00004-0
Food and Drug Administration. Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies. Guidance for Industry. US Department of Health and Human Services, FDA, Silver Spring, MD: Center for Drug Evaluation and Research. 2024. https://www.fda.gov/media/158178/download
Food and Drug Administration. Safety testing of drug metabolites. Guidance for Industry Silver Spring, MD: US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research. 2020. https://www.fda.gov/media/72279/download
Food and Drug Administration. In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme‐ and Transporter‐Mediated Drug Interactions Guidance for Industry. Silver Spring, MD: US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research. 2020. https://www.fda.gov/media/134582/download